The Potential Added Value of Novel Hearing Therapeutics: An Early Health Economic Model for Hearing Loss
To construct an early health economic model to assess the potential added value of novel hearing therapeutics, compared with the current standard of care. We use idiopathic sudden sensorineural hearing loss (ISSNHL) as a case example, because it is a lead indication for several emerging hearing ther...
Uloženo v:
| Vydáno v: | Otology & neurotology Ročník 41; číslo 8; s. 1033 |
|---|---|
| Hlavní autoři: | , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
United States
01.09.2020
|
| Témata: | |
| ISSN: | 1537-4505, 1537-4505 |
| On-line přístup: | Zjistit podrobnosti o přístupu |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | To construct an early health economic model to assess the potential added value of novel hearing therapeutics, compared with the current standard of care. We use idiopathic sudden sensorineural hearing loss (ISSNHL) as a case example, because it is a lead indication for several emerging hearing therapeutics.
A decision analytic model was developed to assess the costs and effects of using novel hearing therapeutics for patients with ISSNHL. This was compared to the current standard of care. Input data were derived from literature searches and expert opinion. The study adopted a healthcare perspective of the UK National Health Service. Four analyses were conducted: 1) headroom, 2) scenario, 3) threshold, 4) sensitivity.
The decision analytic model showed that novel therapeutics for ISSNHL have potential value both in terms of improved patient outcomes, as well as incremental net monetary benefit (iNMB). The base case analysis revealed an iNMB of £39,032 for novel therapeutics compared with the current standard of care. Results of the threshold and scenario analysis revealed that age of treatment and severity of ISSNHL are major determinants of iNMB for novel therapeutics.
This article describes the first health economic model for novel therapeutics for hearing loss; and shows that novel hearing therapeutics can be cost-effective under NICE's cost-effectiveness threshold, with considerable room for improvement in the current standard of care. Our model can be used to inform the development of cost-effective hearing therapeutics; and help decision makers decide which therapeutics represent value for money. |
|---|---|
| AbstractList | To construct an early health economic model to assess the potential added value of novel hearing therapeutics, compared with the current standard of care. We use idiopathic sudden sensorineural hearing loss (ISSNHL) as a case example, because it is a lead indication for several emerging hearing therapeutics.
A decision analytic model was developed to assess the costs and effects of using novel hearing therapeutics for patients with ISSNHL. This was compared to the current standard of care. Input data were derived from literature searches and expert opinion. The study adopted a healthcare perspective of the UK National Health Service. Four analyses were conducted: 1) headroom, 2) scenario, 3) threshold, 4) sensitivity.
The decision analytic model showed that novel therapeutics for ISSNHL have potential value both in terms of improved patient outcomes, as well as incremental net monetary benefit (iNMB). The base case analysis revealed an iNMB of £39,032 for novel therapeutics compared with the current standard of care. Results of the threshold and scenario analysis revealed that age of treatment and severity of ISSNHL are major determinants of iNMB for novel therapeutics.
This article describes the first health economic model for novel therapeutics for hearing loss; and shows that novel hearing therapeutics can be cost-effective under NICE's cost-effectiveness threshold, with considerable room for improvement in the current standard of care. Our model can be used to inform the development of cost-effective hearing therapeutics; and help decision makers decide which therapeutics represent value for money. To construct an early health economic model to assess the potential added value of novel hearing therapeutics, compared with the current standard of care. We use idiopathic sudden sensorineural hearing loss (ISSNHL) as a case example, because it is a lead indication for several emerging hearing therapeutics.OBJECTIVETo construct an early health economic model to assess the potential added value of novel hearing therapeutics, compared with the current standard of care. We use idiopathic sudden sensorineural hearing loss (ISSNHL) as a case example, because it is a lead indication for several emerging hearing therapeutics.A decision analytic model was developed to assess the costs and effects of using novel hearing therapeutics for patients with ISSNHL. This was compared to the current standard of care. Input data were derived from literature searches and expert opinion. The study adopted a healthcare perspective of the UK National Health Service. Four analyses were conducted: 1) headroom, 2) scenario, 3) threshold, 4) sensitivity.METHODSA decision analytic model was developed to assess the costs and effects of using novel hearing therapeutics for patients with ISSNHL. This was compared to the current standard of care. Input data were derived from literature searches and expert opinion. The study adopted a healthcare perspective of the UK National Health Service. Four analyses were conducted: 1) headroom, 2) scenario, 3) threshold, 4) sensitivity.The decision analytic model showed that novel therapeutics for ISSNHL have potential value both in terms of improved patient outcomes, as well as incremental net monetary benefit (iNMB). The base case analysis revealed an iNMB of £39,032 for novel therapeutics compared with the current standard of care. Results of the threshold and scenario analysis revealed that age of treatment and severity of ISSNHL are major determinants of iNMB for novel therapeutics.RESULTSThe decision analytic model showed that novel therapeutics for ISSNHL have potential value both in terms of improved patient outcomes, as well as incremental net monetary benefit (iNMB). The base case analysis revealed an iNMB of £39,032 for novel therapeutics compared with the current standard of care. Results of the threshold and scenario analysis revealed that age of treatment and severity of ISSNHL are major determinants of iNMB for novel therapeutics.This article describes the first health economic model for novel therapeutics for hearing loss; and shows that novel hearing therapeutics can be cost-effective under NICE's cost-effectiveness threshold, with considerable room for improvement in the current standard of care. Our model can be used to inform the development of cost-effective hearing therapeutics; and help decision makers decide which therapeutics represent value for money.CONCLUSIONThis article describes the first health economic model for novel therapeutics for hearing loss; and shows that novel hearing therapeutics can be cost-effective under NICE's cost-effectiveness threshold, with considerable room for improvement in the current standard of care. Our model can be used to inform the development of cost-effective hearing therapeutics; and help decision makers decide which therapeutics represent value for money. |
| Author | May, Carl Mandavia, Rishi Landry, Evie Grutters, Janneke P C Schilder, Anne G M Scholte, Mirre Horstink, Yvette M Rovers, Maroeska |
| Author_xml | – sequence: 1 givenname: Rishi surname: Mandavia fullname: Mandavia, Rishi organization: NIHR, Applied Research Collaborative (ARC) North Thames, UK – sequence: 2 givenname: Yvette M surname: Horstink fullname: Horstink, Yvette M organization: Department of Operating Rooms, Radboud Institute for Health Sciences, Radboud University Medical Centre, Nijmegen, The Netherlands – sequence: 3 givenname: Janneke P C surname: Grutters fullname: Grutters, Janneke P C organization: Department of Operating Rooms, Radboud Institute for Health Sciences, Radboud University Medical Centre, Nijmegen, The Netherlands – sequence: 4 givenname: Evie surname: Landry fullname: Landry, Evie organization: BC Rotary Hearing & Balance Centre, University of British Columbia, Vancouver, BC, Canada – sequence: 5 givenname: Carl surname: May fullname: May, Carl organization: London School of Hygiene and Tropical Medicine, London, UK – sequence: 6 givenname: Maroeska surname: Rovers fullname: Rovers, Maroeska organization: Department of Operating Rooms, Radboud Institute for Health Sciences, Radboud University Medical Centre, Nijmegen, The Netherlands – sequence: 7 givenname: Anne G M surname: Schilder fullname: Schilder, Anne G M organization: NIHR, Applied Research Collaborative (ARC) North Thames, UK – sequence: 8 givenname: Mirre surname: Scholte fullname: Scholte, Mirre organization: Department of Operating Rooms, Radboud Institute for Health Sciences, Radboud University Medical Centre, Nijmegen, The Netherlands |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33169949$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkMtOwzAQRS1URB_wBwh5ySbFzzzYRVWhSC1lUdhGjj2mQU5c4gSpf08RBXU2d6R7zixmjAaNbwCha0qmlGTJ3SpfT8nJsESIMzSikieRkEQOTvYhGofwQQhNuEwu0JBzGmeZyEZou9kCfvEdNF2lHM6NAYPflOsBe4uf_Rc4vADVVs07PqCt2kHfVTrc47zBc9W6_U_tui2ea9_4utJ45c1Bsr79F5c-hEt0bpULcHXMCXp9mG9mi2i5fnya5ctIC5qmEQMTUyt1LLhMGSQlsIwxnaWxpMoCNVrTsjSpoECEpZoRm1AtRcyUFSVwNkG3v3d3rf_sIXRFXQUNzqkGfB8KJmTGJWM8PqA3R7QvazDFrq1q1e6Lv--wb9PfaI4 |
| CitedBy_id | crossref_primary_10_1016_j_clinbiochem_2023_110684 crossref_primary_10_3389_fnins_2022_769983 crossref_primary_10_1097_ONO_0000000000000018 crossref_primary_10_3390_medicina58070963 crossref_primary_10_1007_s40258_022_00774_5 |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1097/MAO.0000000000002744 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1537-4505 |
| ExternalDocumentID | 33169949 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GrantInformation_xml | – fundername: Department of Health grantid: NIHR-RP-011-045 |
| GroupedDBID | --- .-D .GJ .Z2 0R~ 123 1J1 4Q1 4Q2 4Q3 53G 5VS AAAAV AAHPQ AAIQE AAMTA AARTV AASCR AASOK AAWTL AAYEP ABASU ABBUW ABDIG ABJNI ABPXF ABVCZ ABXVJ ABZAD ABZZY ACBNA ACCJW ACDDN ACEWG ACGFS ACILI ACNWC ACWDW ACWRI ACXJB ACXNZ ADFPA ADGGA ADHPY ADNKB AE3 AE6 AEETU AENEX AFBFQ AFDTB AFUWQ AGINI AHQNM AHRYX AHVBC AINUH AJCLO AJIOK AJNWD AJNYG AJZMW AKCTQ ALKUP ALMA_UNASSIGNED_HOLDINGS ALMTX AMJPA AMKUR AMNEI AOHHW AOQMC BQLVK BS7 C45 CGR CUY CVF DIWNM DU5 DUNZO E.X EBS ECM EEVPB EIF EJD EX3 F2K F2L F2M F2N FCALG FL- FW0 GNXGY GQDEL H0~ HLJTE HZ~ IKREB IN~ IPNFZ JF9 JG8 JK3 JK8 K8S KD2 KMI L-C L7B N4W N9A NPM N~M O9- OAG OAH OCUKA ODA OHT OL1 OLV OLZ OPUJH ORVUJ OUVQU OVD OVDNE OWU OWV OWX OWY OWZ OXXIT R58 RIG RLZ S4R S4S T8P TEORI TSPGW V2I VVN W3M WOQ WOW X3V X3W XXN XYM ZFV ZGI ZZMQN 7X8 ADKSD |
| ID | FETCH-LOGICAL-c4188-2ed61f5c643582e7be2922c98651afe1dcc1bbd841e04f1c20f71c5462af4be32 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 5 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000588497000014&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1537-4505 |
| IngestDate | Mon Sep 08 10:56:23 EDT 2025 Sat May 31 02:12:22 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 8 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4188-2ed61f5c643582e7be2922c98651afe1dcc1bbd841e04f1c20f71c5462af4be32 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| PMID | 33169949 |
| PQID | 2459352236 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2459352236 pubmed_primary_33169949 |
| PublicationCentury | 2000 |
| PublicationDate | 2020-09-00 20200901 |
| PublicationDateYYYYMMDD | 2020-09-01 |
| PublicationDate_xml | – month: 09 year: 2020 text: 2020-09-00 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Otology & neurotology |
| PublicationTitleAlternate | Otol Neurotol |
| PublicationYear | 2020 |
| SSID | ssj0017357 |
| Score | 2.3153205 |
| Snippet | To construct an early health economic model to assess the potential added value of novel hearing therapeutics, compared with the current standard of care. We... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 1033 |
| SubjectTerms | Hearing Hearing Loss, Sensorineural - therapy Hearing Loss, Sudden Humans Models, Economic State Medicine |
| Title | The Potential Added Value of Novel Hearing Therapeutics: An Early Health Economic Model for Hearing Loss |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/33169949 https://www.proquest.com/docview/2459352236 |
| Volume | 41 |
| WOSCitedRecordID | wos000588497000014&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3JTsMwELWAIsSFfSmbjMQ1auw4i7mgClH1QEMPBfUWeRkLpCoppO33Y2ehJyQkcsgplixnljeemTcI3RFJwfoB4QHVNkChQDwZSe4Ja_ukH2tKjamGTcRpmkynfNxcuJVNWWVrEytDrQvl7sh7lIXcgYUgeph_em5qlMuuNiM0NlEnsFDGSXU8XWcR4qBi-rRK7bi9_bBtneNxb9R_qakLm8cR5f0OMitnM9j_7zYP0F4DM3G_lotDtAH5EdoZNYn0Y_RuxQOPi4WrFXLfWfOj8ZuYLQEXBqfFCmZ4aJXAOjY8Wbdolfe4n-OKFBnXDUy47WzGbqraDFsM_LPw2TrgE_Q6eJo8Dr1m6IKnGHFaAzoiJlQWqYQJhVgC5ZQqnkQhEQaIVopIqRNGwGeGKOqbmKiQRVQYJiGgp2grL3I4R1j4ARWhr90cUGYCwxPBpAJqtIt7NOui2_YMMyvULlMhciiWZbY-xS46q39ENq_ZN7IgIBHnjF_8YfUl2qUuPq5qwq5Qx1iVhmu0rVaLj_LrppIW-07Ho2-LV8eq |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+Potential+Added+Value+of+Novel+Hearing+Therapeutics%3A+An+Early+Health+Economic+Model+for+Hearing+Loss&rft.jtitle=Otology+%26+neurotology&rft.au=Mandavia%2C+Rishi&rft.au=Horstink%2C+Yvette+M&rft.au=Grutters%2C+Janneke+P+C&rft.au=Landry%2C+Evie&rft.date=2020-09-01&rft.eissn=1537-4505&rft.volume=41&rft.issue=8&rft.spage=1033&rft_id=info:doi/10.1097%2FMAO.0000000000002744&rft_id=info%3Apmid%2F33169949&rft_id=info%3Apmid%2F33169949&rft.externalDocID=33169949 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1537-4505&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1537-4505&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1537-4505&client=summon |